Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis

High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight range of 15-45 kDa, may be one of the reasons for this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephrology, dialysis, transplantation dialysis, transplantation, 2018-01, Vol.33 (1), p.34-43
Hauptverfasser: Trojanowicz, Bogusz, Ulrich, Christof, Fiedler, Roman, Martus, Peter, Storr, Markus, Boehler, Torsten, Werner, Kristin, Hulko, Michael, Zickler, Daniel, Willy, Kevin, Schindler, Ralf, Girndt, Matthias
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 43
container_issue 1
container_start_page 34
container_title Nephrology, dialysis, transplantation
container_volume 33
creator Trojanowicz, Bogusz
Ulrich, Christof
Fiedler, Roman
Martus, Peter
Storr, Markus
Boehler, Torsten
Werner, Kristin
Hulko, Michael
Zickler, Daniel
Willy, Kevin
Schindler, Ralf
Girndt, Matthias
description High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight range of 15-45 kDa, may be one of the reasons for this. Employment of haemodialysis membranes with increased permeability was shown to ameliorate the inflammatory response and might modulate the effects of local RAS. In this study, we tested the impact of high cut-off (HCO), medium cut-off (MCO) and high-flux (HF) dialysis on leucocytic transcripts of angiotensin-converting enzymes (ACE and ACE2). Additionally, the impact of HCO, MCO and HF sera and dialysates on local ACEs and inflammation markers was tested in THP-1 monocytes. Patients' leucocytes were obtained from our recent clinical studies comparing HCO and MCO dialysers with HF. The cells were subjected to quantitaive polymerase chain reaction (qPCR) analyses with TaqMan probes specific for ACE, ACE2 and angiotensin II (AngII) and Ang1-7 receptors. Sera and dialysates from the clinical trials as well as samples from in vitro dialysis were tested on THP-1 monocytic cells. The cells were subjected to qPCR analyses with TaqMan probes specific for ACE, ACE2, interleukin-6 and tumour necrosis factor α and immunocytochemistry with ACE and ACE2 antibodies. Leucocytes obtained from patients treated with HCO or MCO demonstrated decreased transcript expression of ACE, while ACE2 was significantly upregulated as compared with HF. Receptors for AngII and Ang1-7 remained unchanged. THP-1 monocytes preconditioned with HCO and MCO patients' or in vitro dialysis sera reflected the same expressional regulation of ACE and ACE2 as those observed in HCO and MCO leucocytes. As a complementary finding, treatment with HCO and MCO in vitro dialysates induced a pro-inflammatory response of the cells as demonstrated by elevated messenger RNA expression of tumour necrosis factor α and interleukin-6, as well as upregulation of ACE and decreased levels of ACE2. Taken together, these data demonstrate that employment of membranes with high permeability eliminates a spectrum of mediators from circulation that affect the RAS components in leucocytes, especially ACE/ACE2.
doi_str_mv 10.1093/ndt/gfx206
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1949696655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1949696655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-6063c4e7f6a9a64e0270c2d95c4256216c362d2fa641a4f5a5a355f8c1e7d7883</originalsourceid><addsrcrecordid>eNo9kDtPwzAUhS0EoqWw8AOQR4QU6kfsxCOqeElFLDBHrnOTGiV2iB3U8OsJamG4usP5zhk-hC4puaVE8aUr47KudozIIzSnqSQJ47k4RvMppAkRRM3QWQgfhBDFsuwUzViuFGMsnaPxxZdDo6P1DvsKNzAYb8ZoDdautj6CC9Ylxrsv6KN1NQb3PbYQMOy6HkL47VmHu2kBXAy41dbF6aDEU7K19TbpoG9BbxrAWw2tL61uxmDDOTqpdBPg4vAX6P3h_m31lKxfH59Xd-vEcMZjIonkJoWsklppmQJhGTGsVMKkTEhGpeGSlayaMqrTSmihuRBVbihkZZbnfIGu97td7z8HCLFobTDQNNqBH0JBVaqkklKICb3Zo6b3IfRQFV1vW92PBSXFr-piUl3sVU_w1WF32LRQ_qN_bvkPc1N9_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1949696655</pqid></control><display><type>article</type><title>Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>Oxford Journals</source><creator>Trojanowicz, Bogusz ; Ulrich, Christof ; Fiedler, Roman ; Martus, Peter ; Storr, Markus ; Boehler, Torsten ; Werner, Kristin ; Hulko, Michael ; Zickler, Daniel ; Willy, Kevin ; Schindler, Ralf ; Girndt, Matthias</creator><creatorcontrib>Trojanowicz, Bogusz ; Ulrich, Christof ; Fiedler, Roman ; Martus, Peter ; Storr, Markus ; Boehler, Torsten ; Werner, Kristin ; Hulko, Michael ; Zickler, Daniel ; Willy, Kevin ; Schindler, Ralf ; Girndt, Matthias</creatorcontrib><description>High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight range of 15-45 kDa, may be one of the reasons for this. Employment of haemodialysis membranes with increased permeability was shown to ameliorate the inflammatory response and might modulate the effects of local RAS. In this study, we tested the impact of high cut-off (HCO), medium cut-off (MCO) and high-flux (HF) dialysis on leucocytic transcripts of angiotensin-converting enzymes (ACE and ACE2). Additionally, the impact of HCO, MCO and HF sera and dialysates on local ACEs and inflammation markers was tested in THP-1 monocytes. Patients' leucocytes were obtained from our recent clinical studies comparing HCO and MCO dialysers with HF. The cells were subjected to quantitaive polymerase chain reaction (qPCR) analyses with TaqMan probes specific for ACE, ACE2 and angiotensin II (AngII) and Ang1-7 receptors. Sera and dialysates from the clinical trials as well as samples from in vitro dialysis were tested on THP-1 monocytic cells. The cells were subjected to qPCR analyses with TaqMan probes specific for ACE, ACE2, interleukin-6 and tumour necrosis factor α and immunocytochemistry with ACE and ACE2 antibodies. Leucocytes obtained from patients treated with HCO or MCO demonstrated decreased transcript expression of ACE, while ACE2 was significantly upregulated as compared with HF. Receptors for AngII and Ang1-7 remained unchanged. THP-1 monocytes preconditioned with HCO and MCO patients' or in vitro dialysis sera reflected the same expressional regulation of ACE and ACE2 as those observed in HCO and MCO leucocytes. As a complementary finding, treatment with HCO and MCO in vitro dialysates induced a pro-inflammatory response of the cells as demonstrated by elevated messenger RNA expression of tumour necrosis factor α and interleukin-6, as well as upregulation of ACE and decreased levels of ACE2. Taken together, these data demonstrate that employment of membranes with high permeability eliminates a spectrum of mediators from circulation that affect the RAS components in leucocytes, especially ACE/ACE2.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfx206</identifier><identifier>PMID: 28992224</identifier><language>eng</language><publisher>England</publisher><subject>Angiotensin I - metabolism ; Angiotensin-Converting Enzyme 2 ; Biomarkers - metabolism ; Cross-Over Studies ; Dialysis Solutions - metabolism ; Double-Blind Method ; Humans ; Inflammation - enzymology ; Inflammation - pathology ; Inflammation Mediators - blood ; Monocytes - metabolism ; Peptide Fragments - metabolism ; Peptidyl-Dipeptidase A - metabolism ; Pilot Projects ; Receptor, Angiotensin, Type 1 - metabolism ; Receptor, Angiotensin, Type 2 - metabolism ; Renal Dialysis - methods</subject><ispartof>Nephrology, dialysis, transplantation, 2018-01, Vol.33 (1), p.34-43</ispartof><rights>The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-6063c4e7f6a9a64e0270c2d95c4256216c362d2fa641a4f5a5a355f8c1e7d7883</citedby><cites>FETCH-LOGICAL-c323t-6063c4e7f6a9a64e0270c2d95c4256216c362d2fa641a4f5a5a355f8c1e7d7883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28992224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trojanowicz, Bogusz</creatorcontrib><creatorcontrib>Ulrich, Christof</creatorcontrib><creatorcontrib>Fiedler, Roman</creatorcontrib><creatorcontrib>Martus, Peter</creatorcontrib><creatorcontrib>Storr, Markus</creatorcontrib><creatorcontrib>Boehler, Torsten</creatorcontrib><creatorcontrib>Werner, Kristin</creatorcontrib><creatorcontrib>Hulko, Michael</creatorcontrib><creatorcontrib>Zickler, Daniel</creatorcontrib><creatorcontrib>Willy, Kevin</creatorcontrib><creatorcontrib>Schindler, Ralf</creatorcontrib><creatorcontrib>Girndt, Matthias</creatorcontrib><title>Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol Dial Transplant</addtitle><description>High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight range of 15-45 kDa, may be one of the reasons for this. Employment of haemodialysis membranes with increased permeability was shown to ameliorate the inflammatory response and might modulate the effects of local RAS. In this study, we tested the impact of high cut-off (HCO), medium cut-off (MCO) and high-flux (HF) dialysis on leucocytic transcripts of angiotensin-converting enzymes (ACE and ACE2). Additionally, the impact of HCO, MCO and HF sera and dialysates on local ACEs and inflammation markers was tested in THP-1 monocytes. Patients' leucocytes were obtained from our recent clinical studies comparing HCO and MCO dialysers with HF. The cells were subjected to quantitaive polymerase chain reaction (qPCR) analyses with TaqMan probes specific for ACE, ACE2 and angiotensin II (AngII) and Ang1-7 receptors. Sera and dialysates from the clinical trials as well as samples from in vitro dialysis were tested on THP-1 monocytic cells. The cells were subjected to qPCR analyses with TaqMan probes specific for ACE, ACE2, interleukin-6 and tumour necrosis factor α and immunocytochemistry with ACE and ACE2 antibodies. Leucocytes obtained from patients treated with HCO or MCO demonstrated decreased transcript expression of ACE, while ACE2 was significantly upregulated as compared with HF. Receptors for AngII and Ang1-7 remained unchanged. THP-1 monocytes preconditioned with HCO and MCO patients' or in vitro dialysis sera reflected the same expressional regulation of ACE and ACE2 as those observed in HCO and MCO leucocytes. As a complementary finding, treatment with HCO and MCO in vitro dialysates induced a pro-inflammatory response of the cells as demonstrated by elevated messenger RNA expression of tumour necrosis factor α and interleukin-6, as well as upregulation of ACE and decreased levels of ACE2. Taken together, these data demonstrate that employment of membranes with high permeability eliminates a spectrum of mediators from circulation that affect the RAS components in leucocytes, especially ACE/ACE2.</description><subject>Angiotensin I - metabolism</subject><subject>Angiotensin-Converting Enzyme 2</subject><subject>Biomarkers - metabolism</subject><subject>Cross-Over Studies</subject><subject>Dialysis Solutions - metabolism</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>Inflammation - enzymology</subject><subject>Inflammation - pathology</subject><subject>Inflammation Mediators - blood</subject><subject>Monocytes - metabolism</subject><subject>Peptide Fragments - metabolism</subject><subject>Peptidyl-Dipeptidase A - metabolism</subject><subject>Pilot Projects</subject><subject>Receptor, Angiotensin, Type 1 - metabolism</subject><subject>Receptor, Angiotensin, Type 2 - metabolism</subject><subject>Renal Dialysis - methods</subject><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDtPwzAUhS0EoqWw8AOQR4QU6kfsxCOqeElFLDBHrnOTGiV2iB3U8OsJamG4usP5zhk-hC4puaVE8aUr47KudozIIzSnqSQJ47k4RvMppAkRRM3QWQgfhBDFsuwUzViuFGMsnaPxxZdDo6P1DvsKNzAYb8ZoDdautj6CC9Ylxrsv6KN1NQb3PbYQMOy6HkL47VmHu2kBXAy41dbF6aDEU7K19TbpoG9BbxrAWw2tL61uxmDDOTqpdBPg4vAX6P3h_m31lKxfH59Xd-vEcMZjIonkJoWsklppmQJhGTGsVMKkTEhGpeGSlayaMqrTSmihuRBVbihkZZbnfIGu97td7z8HCLFobTDQNNqBH0JBVaqkklKICb3Zo6b3IfRQFV1vW92PBSXFr-piUl3sVU_w1WF32LRQ_qN_bvkPc1N9_g</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Trojanowicz, Bogusz</creator><creator>Ulrich, Christof</creator><creator>Fiedler, Roman</creator><creator>Martus, Peter</creator><creator>Storr, Markus</creator><creator>Boehler, Torsten</creator><creator>Werner, Kristin</creator><creator>Hulko, Michael</creator><creator>Zickler, Daniel</creator><creator>Willy, Kevin</creator><creator>Schindler, Ralf</creator><creator>Girndt, Matthias</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180101</creationdate><title>Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis</title><author>Trojanowicz, Bogusz ; Ulrich, Christof ; Fiedler, Roman ; Martus, Peter ; Storr, Markus ; Boehler, Torsten ; Werner, Kristin ; Hulko, Michael ; Zickler, Daniel ; Willy, Kevin ; Schindler, Ralf ; Girndt, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-6063c4e7f6a9a64e0270c2d95c4256216c362d2fa641a4f5a5a355f8c1e7d7883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Angiotensin I - metabolism</topic><topic>Angiotensin-Converting Enzyme 2</topic><topic>Biomarkers - metabolism</topic><topic>Cross-Over Studies</topic><topic>Dialysis Solutions - metabolism</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>Inflammation - enzymology</topic><topic>Inflammation - pathology</topic><topic>Inflammation Mediators - blood</topic><topic>Monocytes - metabolism</topic><topic>Peptide Fragments - metabolism</topic><topic>Peptidyl-Dipeptidase A - metabolism</topic><topic>Pilot Projects</topic><topic>Receptor, Angiotensin, Type 1 - metabolism</topic><topic>Receptor, Angiotensin, Type 2 - metabolism</topic><topic>Renal Dialysis - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trojanowicz, Bogusz</creatorcontrib><creatorcontrib>Ulrich, Christof</creatorcontrib><creatorcontrib>Fiedler, Roman</creatorcontrib><creatorcontrib>Martus, Peter</creatorcontrib><creatorcontrib>Storr, Markus</creatorcontrib><creatorcontrib>Boehler, Torsten</creatorcontrib><creatorcontrib>Werner, Kristin</creatorcontrib><creatorcontrib>Hulko, Michael</creatorcontrib><creatorcontrib>Zickler, Daniel</creatorcontrib><creatorcontrib>Willy, Kevin</creatorcontrib><creatorcontrib>Schindler, Ralf</creatorcontrib><creatorcontrib>Girndt, Matthias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trojanowicz, Bogusz</au><au>Ulrich, Christof</au><au>Fiedler, Roman</au><au>Martus, Peter</au><au>Storr, Markus</au><au>Boehler, Torsten</au><au>Werner, Kristin</au><au>Hulko, Michael</au><au>Zickler, Daniel</au><au>Willy, Kevin</au><au>Schindler, Ralf</au><au>Girndt, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol Dial Transplant</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>33</volume><issue>1</issue><spage>34</spage><epage>43</epage><pages>34-43</pages><issn>0931-0509</issn><eissn>1460-2385</eissn><abstract>High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight range of 15-45 kDa, may be one of the reasons for this. Employment of haemodialysis membranes with increased permeability was shown to ameliorate the inflammatory response and might modulate the effects of local RAS. In this study, we tested the impact of high cut-off (HCO), medium cut-off (MCO) and high-flux (HF) dialysis on leucocytic transcripts of angiotensin-converting enzymes (ACE and ACE2). Additionally, the impact of HCO, MCO and HF sera and dialysates on local ACEs and inflammation markers was tested in THP-1 monocytes. Patients' leucocytes were obtained from our recent clinical studies comparing HCO and MCO dialysers with HF. The cells were subjected to quantitaive polymerase chain reaction (qPCR) analyses with TaqMan probes specific for ACE, ACE2 and angiotensin II (AngII) and Ang1-7 receptors. Sera and dialysates from the clinical trials as well as samples from in vitro dialysis were tested on THP-1 monocytic cells. The cells were subjected to qPCR analyses with TaqMan probes specific for ACE, ACE2, interleukin-6 and tumour necrosis factor α and immunocytochemistry with ACE and ACE2 antibodies. Leucocytes obtained from patients treated with HCO or MCO demonstrated decreased transcript expression of ACE, while ACE2 was significantly upregulated as compared with HF. Receptors for AngII and Ang1-7 remained unchanged. THP-1 monocytes preconditioned with HCO and MCO patients' or in vitro dialysis sera reflected the same expressional regulation of ACE and ACE2 as those observed in HCO and MCO leucocytes. As a complementary finding, treatment with HCO and MCO in vitro dialysates induced a pro-inflammatory response of the cells as demonstrated by elevated messenger RNA expression of tumour necrosis factor α and interleukin-6, as well as upregulation of ACE and decreased levels of ACE2. Taken together, these data demonstrate that employment of membranes with high permeability eliminates a spectrum of mediators from circulation that affect the RAS components in leucocytes, especially ACE/ACE2.</abstract><cop>England</cop><pmid>28992224</pmid><doi>10.1093/ndt/gfx206</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0931-0509
ispartof Nephrology, dialysis, transplantation, 2018-01, Vol.33 (1), p.34-43
issn 0931-0509
1460-2385
language eng
recordid cdi_proquest_miscellaneous_1949696655
source MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library; Oxford Journals
subjects Angiotensin I - metabolism
Angiotensin-Converting Enzyme 2
Biomarkers - metabolism
Cross-Over Studies
Dialysis Solutions - metabolism
Double-Blind Method
Humans
Inflammation - enzymology
Inflammation - pathology
Inflammation Mediators - blood
Monocytes - metabolism
Peptide Fragments - metabolism
Peptidyl-Dipeptidase A - metabolism
Pilot Projects
Receptor, Angiotensin, Type 1 - metabolism
Receptor, Angiotensin, Type 2 - metabolism
Renal Dialysis - methods
title Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T16%3A30%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modulation%20of%20leucocytic%20angiotensin-converting%20enzymes%20expression%20in%20patients%20maintained%20on%20high-permeable%20haemodialysis&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=Trojanowicz,%20Bogusz&rft.date=2018-01-01&rft.volume=33&rft.issue=1&rft.spage=34&rft.epage=43&rft.pages=34-43&rft.issn=0931-0509&rft.eissn=1460-2385&rft_id=info:doi/10.1093/ndt/gfx206&rft_dat=%3Cproquest_cross%3E1949696655%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1949696655&rft_id=info:pmid/28992224&rfr_iscdi=true